Skip to main content

ORIGINAL RESEARCH article

Front. Health Serv.

Sec. Health Policy and Management

Volume 5 - 2025 | doi: 10.3389/frhs.2025.1465679

Prescription of nirmatrelvir/ritonavir for Covid-19 by general practitioners in Italy: territorial ubiquity and differences

Provisionally accepted
  • 1 Italian Medicines Agency (AIFA), Rome, Italy
  • 2 Department of Political Science, University of Naples Federico II, Naples, Campania, Italy

The final, formatted version of the article will be published soon.

    The availability of nirmatrelvir/ritonavir as a therapeutic option in the management of COVID-19 disease has been important in the clinical management of outpatients. The need to take this drug within 5 days of symptom onset, as prescribed by a physician, has led to disparities, in access, particularly in some countries. Given the clinical and logistical challenges of drug access, the policy differences between countries, and evidence of inequalities, an analysis of nirmatrelvir/ritonavir prescribing in Italy was undertaken. The aim of this study is to assess whether prescribing by General Practitioners (GPs) and distribution by pharmacies actually ensured territorial homogeneity. An ecological study was carried out to assess whether there were subgroups of patients who did not use this drug or GPs who did not prescribe it and whether the therapeutic plan, which had to be reported by the GP, ensured adherence to guidelines. Additionally, we examined whether patient and GP characteristics influenced prescribing patterns through an analytical study. This is the first nationwide study of nirmatrelvir/ritonavir prescribing and its determinants in relation to patient and GP characteristics. The results show that the Italian drug prescribing and dispensing model ensured pharmacoequity, despite potential barriers such as social inequalities, the therapeutic window, the need for a doctor's visit, and potential Drug-Drug Interactions. Although the descriptive analysis and logistic model of GPs prescribing propensity analyse different outcomes, the results show that age is the main driver of prescribing, geographic area has an impact, and residence in a larger municipality results in more prescriptions.

    Keywords: pharmacoequity, Prescribing behavior, GPS, nirmatrelvir/ritonavir, COVID-19

    Received: 16 Jul 2024; Accepted: 10 Feb 2025.

    Copyright: © 2025 DI FILIPPO, Zito, Bellini, Simone and Trotta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: AURORA DI FILIPPO, Italian Medicines Agency (AIFA), Rome, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more